Extended Data Fig. 7: Deletion of RASH3D19 sensitizes mutant KRAS expressing PDAC, CRC, and NSCLC cells to RAS inhibitors.
From: RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer

a, Cell viability assays of AsPC1 and MIAPaCa2 cells which were transfected with control sgRNA or sgRNAs targeting RASH3D19 cultured in 3D for 24 h and then treated with different concentrations of MRTX1133 or AMG510 for 3 days. b, RASH3D19 expression levels in SW837, H1972 and MIAPaCa2 cells prepared as in (a). Bar graphs are represented as mean ± SD. P values were calculated using two-sided unpaired Student’s t-tests. ***, P < 0.001. c, Cell viability assay of sgControl and sgRASH3D19 AsPC1 and PANC1 cells which were cultured in 3D for 24 h followed by treatment with different concentrations of RMC4550 for 3 days. All in vitro assays are representative of three independent experiments.